First Albany Downgrades Conmed to 'Neutral'

Analyst William Plovanic says second-quarter results may fall short of his estimates

First Albany downgraded Conmed (CNMD ) to neutral from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.